menu
    • menu

    Company profile for Orphan Technologies

    NEW Drugs in Dev: 1
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Orphan Technologies is dedicated to developing novel therapies to dramatically improve the lives of patients suffering from the rare disorder, classical homocystinuria, and related diseases. OT-58, our lead drug development candidate, has been optimized as an enzyme therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58...
    Orphan Technologies is dedicated to developing novel therapies to dramatically improve the lives of patients suffering from the rare disorder, classical homocystinuria, and related diseases. OT-58, our lead drug development candidate, has been optimized as an enzyme therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Orphan TechnologiesSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Zuercherstrasse 19 CH-8640 Rapperswil
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://travere.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orphantechnologies/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Retrophin Completes Acquisition of Orphan TechnologiesAddition of OT-58
    Retrophin Completes Acquisition of Orphan TechnologiesAddition of OT-58

    12 Nov 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/retrophin-completes-acquisition-of-orphan-technologiesaddition-of-ot-58-strengthens-pipeline-of-potential-first-in-class-therapies-targeting-rare-diseases/?s=79

    BIOSPACE
    12 Nov 2020
    Share Share
    Retrophin Announces Agreement to Acquire Orphan Technologies
    Retrophin Announces Agreement to Acquire Orphan Technologies

    23 Oct 2020

    // PRESS RELEASE

    http://ir.retrophin.com/news-releases/news-release-details/retrophin-announces-agreement-acquire-orphan-technologies#:~:text=(NASDAQ%3A%20RTRX)%20today%20announced,of%20classical%20homocystinuria%20(HCU).

    PRESS RELEASE
    23 Oct 2020
    Share Share
    Retrophin Announces Agreement to Acquire Orphan Technologies
    Retrophin Announces Agreement to Acquire Orphan Technologies

    22 Oct 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/retrophin-announces-agreement-to-acquire-orphan-technologies/?s=79

    BIOSPACE
    22 Oct 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search